#immune thrombocytopenia epidemiology

[kritikarehani]

Immune Thrombocytopenia (ITP) Market Scenario, 2030

DelveInsight’s ‘Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the ITP, historical and forecasted epidemiology as well as the ITP market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2017–2030

View report: https://www.delveinsight.com/sample-request/immune-thrombocytopenia-market

Immune Thrombocytopenia (ITP) Disease Understanding

Immune Thrombocytopenia (ITP) Overview

Immune Thrombocytopenia (ITP), previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its platelets and destroys them too quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function. Many of the symptoms of ITP stem from a low platelet count leading to excessive bleeding. In severe cases, frequent bleeding episodes may result in low levels of circulating red blood cells (anemia), which may cause fatigue and impair response to exertion. In rare cases, serious bleeding into the brain (intracranial hemorrhage) may occur.

The two main types of ITP are acute (short term) and chronic (long term). ITP is also categorized as primary and secondary based on the cause of the disease. ITP in the absence of other causes or disorders that may be associated with the thrombocytopenia is known as primary ITP, whereas, secondary ITP refers to immune-mediated thrombocytopenia with an underlying cause, including drug-induced, or associated with systemic illness (e.g., systemic lupus erythematosus, infection [e.g., HIV], immune deficiency [e.g., common variable immunodeficiency or autoimmune lymphoproliferative syndrome], and other causes).

Immune Thrombocytopenia (ITP) Epidemiology  

The Immune Thrombocytopenia epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of ITP, Total Diagnosed Prevalent Population of ITP, and Gender-specific Diagnosed Prevalent Population of ITP scenario of ITP in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Key Findings

·         Assessments as per DelveInsight’s analysts show that the majority of cases of ITP are females as compared to males. There was a total of 32,364 female and 20,998 male diagnosed cases of ITP in 2017 in the United States.

·         DelveInsight’s estimations suggest that the total prevalent population ITP in the seven major markets was approximately 180,498 in 2017.

·         The total diagnosed prevalent cases in the 7MM was estimated to be approximately 147,174 in 2017.

Immune Thrombocytopenia (ITP) Epidemiology

The epidemiology segment also provides the ITP epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Download our free report: https://www.delveinsight.com/sample-request/immune-thrombocytopenia-market

Immune Thrombocytopenia (ITP) Drug Chapters

The drug chapter segment of the ITP report encloses the detailed analysis of Immune Throbocytopenia marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the ITP clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Immune Thrombocytopenia (ITP) Marketed Drugs

Tavalisse (fostamatinib disodium hexahydrate): Rigel Pharmaceuticals

Fostamatinib disodium (also known as Tavalisse; R-985788) is an orally-bioavailable investigational agent being developed by Rigel pharmaceuticals and approved for the treatment of patients suffering from persistent/chronic adult idiopathic thrombocytopenic purpura. The therapeutic candidate inhibits FcR-triggered, Syk-dependent cytoskeletal rearrangement during phagocytosis.

As stated by Rigel Pharmaceuticals, fostamatinib has a unique mechanism of action, blocking IgG receptor signaling in both macrophages and B cells via SYK kinase. The company is focusing on the fostamatinib ITP program specifically on the chronic form of this disease targeting the underlying autoimmune cause of the disease rather than stimulating platelet production. Moreover, fostamatinib is also being evaluated for autoimmune hemolytic anemia, IgA nephropathy, graft-versus-host disease, and ovarian cancer.

In June 2017, the company filed for the New Drug Application to the USFDA for the use of fostamatinib in chronic ITP patients. Later in October 2017, Rigel Pharmaceuticals indicated that the FDA anticipated the Prescription Drug User Fee Act (PDUFA) action date for the application review in April 2018. And in April 2018, Tavalisse got approved for the treatment of Idiopathic Thrombocytopenic Purpura.

Products detail in the report…

List to be continued in the report…

Immune Thrombocytopenia (ITP) Emerging Drugs

BT-595: Biotest

BT-595 (IgG Next Generation) is an intravenously administered, novel polyvalent immunoglobulins (IVIG) designed specifically to treat primary immune deficiencies, secondary antibody deficiency syndromes, and several autoimmune disorders. Currently, the company is developing this therapeutic molecule in the Phase III stage of development for the treatment of patients with Immune Thrombocytopenic Purpura (ITP).

Products detail in the report…

Immune Thrombocytopenia (ITP) Market Outlook

The US Food and Drug Administration (FDA) has approved three Thrombopoietin receptor agonist (TPO-RA) therapies: romiplostim (Nplate), eltrombopag (Promacta), and avatrombopag (Doptelet). For Europe and Japan, only two TPO-RAs is approved, i.e., Nplate and Promacta. Promacta and Nplate will lose their patent in 2022 in the US, whereas, in Europe and Japan, Nplate loses the patent in 2019 and Promacta will lose patent in 2025. Due to their patent expiry, it is expected that the approval of Doptelet is likely to cover a major patient pool.

At present, there have been few well-designed randomized trials targeted at reducing chronic ITP in adults and children. Further prospective trials may be able to enhance the approach and improve overall outcomes. Adequate long-term follow-up will be necessary to determine whether relapse is truly averted or simply delayed. It will also be important to select novel composite outcomes that account for clinical events as well as evaluate the cost and the added adverse events of combined therapies.

In addition to clinical trials, essential research should focus on identifying patients who would benefit from more intensive therapy: for example, the ability to determine those patients who will develop persistent or chronic ITP or identification of markers predictive of who would benefit most from a specific therapy.

According to DelveInsight, ITP 7MM is expected to change in the study period 2017–2030.

Key Findings

·         The Immune Thrombocytopenia market size in the 7MM was found to be USD 2,527.72 million in 2017.

·         The United States accounts for the highest market size of Immune Thrombocytopenia (ITP), in comparison to the other major markets i.e., EU5 countries, and Japan

Request for sample pages of the report, Immune Thrombocytopenia (ITP) Market Outlook: https://www.delveinsight.com/sample-request/immune-thrombocytopenia-market

Download our full report@ https://www.delveinsight.com/report-store/immune-thrombocytopenia-market

[atlanticcanada]

Nova Scotia opens COVID-19 vaccine appointments for people 70 and older

Any Nova Scotian age 70 and older can now book an appointment to receive their COVID-19 vaccine.

Beginning Thursday, Nova Scotians ages 70-74 can book appointments at community clinics or participating pharmacies across the province. Clinics are offering the Moderna or Pfizer vaccines for that age range.

The province opened community vaccination for Nova Scotians over 80 on Feb. 22. On March 26, the province expanded eligibility to include those in the 75-79 age range.

COVID-19 vaccination appointments must be made at the province's vaccine website or by calling 1-833-797-7772. Appointments cannot be booked directly through a community clinic, pharmacy or physician. Walk-ins will be turned away.

AGES 55-64 ELIGIBLE FOR ASTRAZENECA VACCINE APRIL 6

The province also announced that beginning April 6, Nova Scotians ages 55 to 64 will be able to book appointments to receive AstraZeneca vaccine at participating physician and pharmacy clinics.

On Tuesday, Nova Scotia that they will continue to administer the AstraZeneca vaccine for individuals ages 55-64, after suspending the use of the vaccine for individuals under 55 on Monday.

“Anyone 55 or over can still get this vaccine if given the choice, as the benefits of getting the AstraZeneca vaccine outweigh the increased risk of COVID-19 in older adults,” said chief medical officer of health Dr. Robert Strang.

On Monday, the National Advisory Committee on Immunization (NACI) recommended pausing administration of the AstraZeneca vaccine to those under the age of 55, pending further investigation on reported cases of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT), a rare blood clotting disorder, in Europe.

“In the past few weeks there has been an increasing number of reports from Europe of rare but serious cases of blood clots, following immunization with the AstraZeneca vaccine,” said Strang during Tuesday's news conference. “At this time a definitive link between the vaccine and the blood clotting vents has not been made, but it is very suggestive, the evidence to date.”

Strang says that he has had many conversations with Public Health officials from across the country, and the consensus is that the benefit of AstraZeneca outweighs the risk for those in the 55-64 age group.

“We know looking at the epidemiology of this it higher risk of blood clots seems to be mostly women under 55," said Strang. We’ve had a lot of conversation about this, and part of this is what is the risk/benefit. As you get to the ages 55 and above, it seems there is a much lower risk of this blood clotting happening, and the risk of getting serious outcomes from a COVID-19 infection substantially increases.”

“I know this might be scary for people, especially if they have had their first dose of the AstraZeneca vaccine already, but we’re fortunate that in Nova Scotia, our use of the AstraZeneca vaccine has been focused on the ages 60 to 64, which is well within the age range recommended for use.”

Strang says anyone who has received the AstraZeneca vaccine in the last 20 days, and anyone vaccinated with it going forward should monitor for symptoms and seek immediate medical attention in the unlikely event that they develop the following symptoms:

Shortness of breath

Chest pain

Leg swelling

Persistent abdominal pain

Sudden onset of severe or persistent headaches or blurred vision

Skin bruising other than at the site of vaccination

All Nova Scotians are encouraged to get vaccinated against COVID-19 as soon as they are eligible. The province's goal continues to be to immunize as many Nova Scotians as quickly as possible, based on age, to reach a high rate of population immunity.

from CTV News - Atlantic https://ift.tt/39yeXE9

[mi6-rogue]

Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older

Preliminary report; Background: Monitoring safety outcomes following COVID-19 vaccination is critical for understanding vaccine safety especially when used in key populations such as elderly persons age 65 years and older who can benefit greatly from vaccination. We present new findings from a nationally representative early warning system that may expand the safety knowledge base to further public trust and inform decision making on vaccine safety by government agencies, healthcare providers, interested stakeholders, and the public. Methods: We evaluated 14 outcomes of interest following COVID-19 vaccination using the US Centers for Medicare & Medicaid Services (CMS) data covering 30,712,101 elderly persons. The CMS data from December 11, 2020 through Jan 15, 2022 included 17,411,342 COVID-19 vaccinees who received a total of 34,639,937 doses. We conducted weekly sequential testing and generated rate ratios (RR) of observed outcome rates compared to historical (or expected) rates prior to COVID-19 vaccination. Findings: Four outcomes met the threshold for a statistical signal following Pfizer-BioNTech vaccination including pulmonary embolism (PE; RR=1.54), acute myocardial infarction (AMI; RR=1.42), disseminated intravascular coagulation (DIC; RR=1.91), and immune thrombocytopenia (ITP; RR=1.44). After further evaluation, only the RR for PE still met the statistical threshold for a signal; however, the RRs for AMI, DIC, and ITP no longer did. No statistical signals were identified following vaccination with either the Moderna or Janssen vaccines. Interpretation: This early warning system is the first to identify temporal associations for PE, AMI, DIC, and ITP following Pfizer-BioNTech vaccination in the elderly. Because an early warning system does not prove that the vaccines cause these outcomes, more robust epidemiologic studies with adjustment for confounding factors, including age and nursing home residency, are underway to further evaluate these signals. FDA strongly believes the potential benefits of COVID-19 vaccination outweigh the potential risks of COVID-19 infection. https://www.medrxiv.org/content/10.1101/2022.11.04.22281910v1?rss=1%22&utm_source=dlvr.it&utm_medium=tumblr Read more ↓

[didanawisgi]

FDA urged to publish follow-up studies on covid-19 vaccine safety signals

[decentralvaccine]

FDA Encouraged To Follow Through On Covid 19 Vaccine Safety Research

The FDA has been criticised for taking more than a year to follow up a potential increase in serious adverse events in elderly people receiving Pfizer’s covid-19 vaccine, Maryanne Demasi reports

In July 2021 the US Food and Drug Administration (FDA) quietly disclosed findings of a potential increase in four types of serious adverse events in elderly people who had had Pfizer’s covid-19 vaccine: acute myocardial infarction, disseminated intravascular coagulation, immune thrombocytopenia, and pulmonary embolism.1 Little detail was provided, such as the magnitude of the increased potential risk, and no press release or other alert was sent to doctors or the public. The FDA promised it would “share further updates and information with the public as they become available.”

Eighteen days later, the FDA published a study planning document (or protocol) outlining a follow-up epidemiological study intended to investigate the matter more thoroughly.2 This recondite technical document disclosed the unadjusted relative risk ratio estimates originally found for the four serious adverse events, which ranged from 42% to 91% increased risk. (Neither absolute risk increases nor confidence intervals were provided.) More than a year later, however, the status and results of the follow-up study are unknown. The agency has not published a press release, or notified doctors, or published the findings by preprint or the scientific literature or updated the vaccine’s product label.

The BMJ has also learnt that the FDA has not publicly warned of similar signals detected in a separate observational cohort study it conducted of the third dose (first booster dose) in the elderly,3 nor has the agency publicly acknowledged other published observational studies or clinical trial reanalyses reporting compatible results. Experts spoke to The BMJ about their concerns about the data and have called on the FDA to notify the public immediately.

https://www.bmj.com/content/379/bmj.o2527

[orbemnews]

Blood Clots Linked to AstraZeneca Vaccine Stem From Rare Antibody Reaction Two reports published on Friday in a leading medical journal help to explain how AstraZeneca’s Covid vaccine can, in rare cases, cause serious and sometimes fatal blood clots. Scientific teams from Germany and Norway found that people who developed the clots after vaccination had produced antibodies that activated their platelets, a blood component involved in clotting. The new reports add extensive details to what the researchers have already stated publicly about the blood disorder. Why the rare reaction occurred is not known. Younger people appear more susceptible than older ones, but researchers say no pre-existing health conditions are known to predispose people to the problem, so there is no way to tell if an individual is at high risk. Reports of the clots have already led a number of countries to limit AstraZeneca’s vaccine to older people, or to stop using it entirely. The cases have dealt a crushing blow to global efforts to halt the pandemic, because the AstraZeneca shot — easy to store and relatively cheap — has been a mainstay of vaccination programs in more than 100 countries. Regulators in Europe have emphasized that the clotting disorder is rare, and that the vaccine’s benefits far outweigh its risks. But when a side effect has the potential to be devastating or fatal — like the blood clots in the brain linked to this vaccine — some regulators and segments of the public find the risk unacceptable, even if it is extremely rare. As of Sunday, European regulators had received reports of 222 cases of the rare blood-clotting problem in Britain and the 30-nation European Economic Area (the European Union plus Iceland, Norway and Liechtenstein). They said that about 34 million people had received the AstraZeneca vaccine in those countries, and that the clotting problems were appearing at a rate of about one in 100,000 recipients. European regulators said that as of March 22, they had carried out detailed reviews of 86 cases, 18 of which had been fatal. The safety bar for vaccines is set high, because they are given to healthy people. The seemingly greater vulnerability of younger people to the clotting disorder is of particular concern, because their risk of severe illness from Covid itself is lower than that in older people. Those differences suggest that overall, compared to older people, younger people may have less to gain and more to lose from the AstraZeneca vaccine. Germany, the Netherlands, the Philippines, Portugal and Spain have recommended that the AstraZeneca vaccine be given only to people over 60. Canada and France have limited it to those over 55; Australia, over 50; Belgium, over 56. Britain, where the vaccine was developed, has been its staunchest defender, but announced on Wednesday that it would begin offering alternative shots to people under 30. Cameroon, the Democratic Republic of Congo, Denmark and Norway have stopped using the vaccine. Full vaccination with the AstraZeneca vaccine requires two doses, but regulators in France have recommended that people under 55 who have had one dose get a different vaccine for their second shot. The AstraZeneca vaccine is not authorized for use in the United States, but the Food and Drug Administration is reviewing data on it to determine whether it should be. On Wednesday, the European Medicines Agency said that the vaccine’s labeling should be revised to include listing the clotting disorder as a “very rare” side effect of the vaccine. In a statement on its website, AstraZeneca said it was “actively collaborating with the regulators to implement these changes to the product information and is already working to understand the individual cases, epidemiology and possible mechanisms that could explain these extremely rare events.” The two new reports were published by The New England Journal of Medicine. One from Germany describes 11 patients, including nine women ages 22 to 49. Five to 16 days after vaccination, they were found to have one or more clots. Nine had cerebral venous thrombosis, a clot blocking a vein that drains blood from the brain. Some had clots in their lungs, abdomen or other areas. Six of the 11 died, one from a brain hemorrhage. One patient had pre-existing conditions that affected clotting, but during a news briefing on Friday, Dr. Andreas Greinacher, an author of the report, said those conditions most likely played only a minor role in the disorder that occurred after vaccination. All the patients, as well as 17 others with clots after vaccination whose blood was tested, had antibodies known to activate platelets. The antibodies led to a condition called thrombotic thrombocytopenia, which causes both clotting and abnormal bleeding. The researchers suggested naming the newly identified version in these patients “vaccine-induced immune thrombotic thrombocytopenia.” The article described specialized blood tests that can be used to diagnose the disorder, and suggested treatment with a blood product called intravenous immune globulin, which is used to treat various immune disorders. Drugs called anti-coagulants, or blood thinners, can also be administered in some cases, but not a commonly used one, heparin — because the vaccine-related condition is very similar to one that occurs, rarely, in people given heparin. The second report, from Norway, described five patients, one male and four female health care workers ages 32 to 54, who had clots and bleeding from seven to 10 days after receiving the AstraZeneca vaccine. Four had severe clots in the brain, and three died. Severe headaches were among their early symptoms. Like the German patients, all had high levels of antibodies that could activate platelets. The team from Norway also recommended treatment with intravenous immune globulin. The researchers said the disorder was rare, but “a new phenomenon with devastating effects for otherwise healthy young adults,” and they suggested that it may be more common than previous studies of the AstraZeneca vaccine had indicated. On Friday, European regulators also said they were reviewing reports of a few blood clot cases that occurred in people who had received the Johnson and Johnson vaccine. In the United States, federal agencies are investigating reports of a different type of unusual blood disorder involving a precipitous drop in platelets that emerged in a few people who had received either the Pfizer-BioNTech or Moderna vaccines. Benjamin Mueller and Melissa Eddy contributed. Source link Orbem News #Antibody #AstraZeneca #blood #Clots #Linked #rare #reaction #stem #Vaccine

[kritikarehani]

Immune Thrombocytopenia Market 

The market size of Immune Thrombocytopenia in 7MM was USD 2527.72 Million in 2017. 

The total prevalent population of Immune Thrombocytopenia in the 7MM is estimated to be approximately 184,676 in 2020.

The key players in the Immune Thrombocytopenia market include Octapharma USA, Amgen, CSL Behring, Dova Pharmaceuticals, Rigel Pharmaceuticals, Novartis, Bio Products Laboratory, Takeda, AstraZeneca, Biotest, SK Plasma, Argenx, Kezar Life Sciences, UCB Biopharma, Bristol-Myers Squibb, Principia Biopharma, Protalex and others.

For more detailed information visit: 

https://www.delveinsight.com/report-store/immune-thrombocytopenia-market

[affiliatetejas]

Immunoglobulin Market Sales Size Share Forecast 2027

Main link -

https://www.coherentmarketinsights.com/ongoing-insight/immunoglobulin-market-1712

To Gain More Insights into the Immunoglobulin Market, Browse Summary of the Research Report –

Immunoglobulins are critical part of the immune response, which specifically recognize and bind to particular antigens such as bacteria or viruses aiding in their inhibition. Immunoglobulins also called as antibodies are the glycoprotein molecules produced by plasma cells i.e. white blood cells. The antibody immune response is highly complex and very specific. The various immunoglobulin classes and subclasses (isotypes) differ in their biological features, structure, target specificity and distribution. Hence, the assessment of the immunoglobulin isotype can provide useful insight into complex humoral immune response.

There are different classes of immunoglobulin such as IgG, IgA, and IgM, which are used for the treatment of various immunological and neurological diseases. These immunoglobulins can be administered intravenously and subcutaneously.

Immunoglobulin are used in treatment of autoimmune diseases such as multiple sclerosis, Primary Humoral Immunodeficiency (PIDD), Immune Thrombocytopenia Purpura (ITP), and autoimmune haemolytic anemia. Furthermore, immunoglobulin have applications in various other field such as hematology, neurology, immunology, dermatology, ophthalmology, nephrology and rheumatology, which is driving growth of the immunoglobulin market.

“We Do Offer Sample of Immunoglobulin Market report. Kindly go through the follow information in order to access sample copy.”

https://www.coherentmarketinsights.com/insight/request-sample/1712

Table of Contents

Research Objectives and Assumptions

Research Objectives

Assumptions

Abbreviations

Market Purview

Report Description

Market Definition and Scope

Executive Summary

Market Snippet, By Drug Type

Market Snippet, By Distribution Channel

Market Snippet, By Region

Coherent Opportunity Map (COM)

Market Dynamics, Regulations, and Trends Analysis

Market Dynamics

Drivers

Restraints

Market Opportunities

Impact Analysis

Market Trends

Regulatory Scenario

Reimbursement Scenario

Epidemiology

PEST Analysis

Recent Product Launch

Merger and Acquisition Scenario

Top players in the market

The major players operating in the market include Baxter international Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., BDI Pharma Inc., and Bayer Healthcare. Other players in the immunoglobulin market include Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd., Behring GmbH, Shanghai RAAS Blood Products Co., Ltd., Option Care Enterprises, Inc., ADMA Biologics, Inc., and BioScrip, Inc.

Immunoglobulin manufactures are involved in research and development to develop new immunoglobulin drug. For instance, GigaGen received US$ 3 million grant from the National Institutes of Health in January 2018, to develop novel antibody therapies to advance its next-generation plasma therapy for patients with immune deficiencies

Research methodology adopted by Coherent Market Insights

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

Primary Research (Trade Surveys and Experts Interviews)

Desk Research

Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.

Request A Sample Copy –Immunoglobulin Market Report Click here:

https://www.coherentmarketinsights.com/insight/request-sample/1712

Get PDF Research Report Brochure @

https://www.coherentmarketinsights.com/insight/request-pdf/1712

Buy Now this Premium Report to Grow your Business @

https://www.coherentmarketinsights.com/ongoing-insight/toc/1712

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

Contact Us:

Name: Mr. Raj Shah

Email: sales@coherentmarketinsights.com

Phone: US +12067016702

Country: United States

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

[kon-igi]

O LEGGETE E CAPITE TUTTO OPPURE VI FIDATE

In 1900, for every 1,000 babies born in the United States, 100 would die before their first birthday, often due to infectious diseases. Today, vaccines exist for many viral and bacterial diseases. The National Childhood Vaccine Injury Act, passed in 1986, was intended to bolster vaccine research and development through the federal coordination of vaccine initiatives and to provide relief to vaccine manufacturers facing financial burdens. The legislation also intended to address concerns about the safety of vaccines by instituting a compensation program, setting up a passive surveillance system for vaccine adverse events, and by providing information to consumers. A key component of the legislation required the U.S. Department of Health and Human Services to collaborate with the Institute of Medicine to assess concerns about the safety of vaccines and potential adverse events, especially in children. Adverse Effects of Vaccines reviews the epidemiological, clinical, and biological evidence regarding adverse health events associated with specific vaccines covered by the National Vaccine Injury Compensation Program (VICP), including the varicella zoster vaccine, influenza vaccines, the hepatitis B vaccine, and the human papillomavirus vaccine, among others. For each possible adverse event, the report reviews peer-reviewed primary studies, summarizes their findings, and evaluates the epidemiological, clinical, and biological evidence. It finds that while no vaccine is 100 percent safe, very few adverse events are shown to be caused by vaccines. In addition, the evidence shows that vaccines do not cause several conditions. For example, the MMR vaccine is not associated with autism or childhood diabetes. Also, the DTaP vaccine is not associated with diabetes and the influenza vaccine given as a shot does not exacerbate asthma.

Adverse Effects of Vaccines will be of special interest to the National Vaccine Program Office, the VICP, the Centers for Disease Control and Prevention, vaccine safety researchers and manufacturers, parents, caregivers, and health professionals in the private and public sectors.

Contents

Expand All

Collapse All

THE NATIONAL ACADEMIES

COMMITTEE TO REVIEW ADVERSE EFFECTS OF VACCINES

Reviewers

Preface

Acronyms

Summary

1. Introduction

2. Approach

3. Evaluating Biological Mechanisms of Adverse Events

4. Measles, Mumps, and Rubella Vaccine

5. Varicella Virus Vaccine

6. Influenza Vaccine

7. Hepatitis A Vaccine

8. Hepatitis B Vaccine

9. Human Papillomavirus Vaccine

10. Diphtheria Toxoid–, Tetanus Toxoid–, and Acellular Pertussis–Containing Vaccines

11. Meningococcal Vaccine

12. Injection-Related Adverse Events

13. Concluding Comments

APPENDIXES

CHARGE TO THE COMMITTEE

ASSESSING THE WEIGHT OF EVIDENCE

CAUSALITY ASSESSMENT

CAUSALITY CONCLUSIONS

SUSCEPTIBILITY

CONCLUDING COMMENT

REFERENCES

CHARGE TO THE COMMITTEE

COMMITTEE PROCESS

OUTLINE OF THE REPORT

REFERENCES

LITERATURE SEARCHING

WEIGHT OF EVIDENCE

CAUSALITY ASSESSMENT

SPECIAL CONSIDERATIONS

REFERENCES

LATENCY BETWEEN ANTIGEN EXPOSURE AND PEAK ADAPTIVE IMMUNE RESPONSE

IMMUNE-MEDIATED MECHANISMS

VIRAL ACTIVITY

INJECTION-RELATED ADVERSE EVENTS

COAGULATION AND HYPERCOAGULABLE STATES

INCREASED SUSCEPTIBILITY

ALTERATIONS IN BRAIN DEVELOPMENT

CONTRIBUTION OF ANIMAL MODELS

REFERENCES

INTRODUCTION

MEASLES INCLUSION BODY ENCEPHALITIS

ENCEPHALITIS AND ENCEPHALOPATHY

FEBRILE SEIZURES

AFEBRILE SEIZURES

MENINGITIS

ATAXIA

AUTISM

ACUTE DISSEMINATED ENCEPHALOMYELITIS

TRANSVERSE MYELITIS

OPTIC NEURITIS

NEUROMYELITIS OPTICA

MULTIPLE SCLEROSIS ONSET IN ADULTS

MULTIPLE SCLEROSIS ONSET IN CHILDREN

GUILLAIN-BARRÉ SYNDROME

CHRONIC INFLAMMATORY DISSEMINATED POLYNEUROPATHY

OPSOCLONUS MYOCLONUS SYNDROME

BRACHIAL NEURITIS

ANAPHYLAXIS

TRANSIENT ARTHRALGIA IN WOMEN

TRANSIENT ARTHRALGIA IN CHILDREN

CHRONIC ARTHRALGIA IN WOMEN

CHRONIC ARTHRITIS IN WOMEN

CHRONIC ARTHROPATHY IN CHILDREN

ARTHROPATHY IN MEN

TYPE 1 DIABETES

HEPATITIS

CHRONIC FATIGUE SYNDROME

FIBROMYALGIA

HEARING LOSS

CONCLUDING SECTION

REFERENCES

INTRODUCTION

DISSEMINATED OKA VZV WITHOUT OTHER ORGAN INVOLVEMENT

DISSEMINATED OKA VZV WITH OTHER ORGAN INVOLVEMENT

VACCINE-STRAIN VIRAL REACTIVATION WITHOUT OTHER ORGAN INVOLVEMENT

VACCINE-STRAIN VIRAL REACTIVATION WITH OTHER ORGAN INVOLVEMENT

ENCEPHALOPATHY

SEIZURES

CEREBELLAR ATAXIA

ACUTE DISSEMINATED ENCEPHALOMYELITIS

TRANSVERSE MYELITIS

GUILLAIN-BARRÉ SYNDROME

SMALL FIBER NEUROPATHY

ANAPHYLAXIS

ONSET OR EXACERBATION OF ARTHROPATHY

STROKE

THROMBOCYTOPENIA

CONCLUDING SECTION

REFERENCES

INTRODUCTION

ENCEPHALITIS AND ENCEPHALOPATHY

SEIZURES

ACUTE DISSEMINATED ENCEPHALOMYELITIS

TRANSVERSE MYELITIS

OPTIC NEURITIS

NEUROMYELITIS OPTICA

MULTIPLE SCLEROSIS ONSET IN ADULTS

MULTIPLE SCLEROSIS RELAPSE IN ADULTS

GUILLAIN-BARRÉ SYNDROME

CHRONIC INFLAMMATORY DISSEMINATED POLYNEUROPATHY

BELL'S PALSY

BRACHIAL NEURITIS

SMALL FIBER NEUROPATHY

ANAPHYLAXIS

INACTIVATED INFLUENZA VACCINE AND ASTHMA EXACERBATION OR REACTIVE AIRWAY DISEASE EPISODES IN CHILDREN AND ADULTS

LIVE ATTENUATED INFLUENZA VACCINE AND ASTHMA EXACERBATION OR REACTIVE AIRWAY DISEASE EPISODES IN CHILDREN YOUNGER THAN 5 YEARS OF AGE

LIVE ATTENUATED INFLUENZA VACCINE AND ASTHMA EXACERBATION OR REACTIVE AIRWAY DISEASE EPISODES IN PERSONS 5 YEARS OF AGE OR OLDER

ONSET OR EXACERBATION OF SYSTEMIC LUPUS ERYTHEMATOSUS

ONSET OR EXACERBATION OF VASCULITIS

POLYARTERITIS NODOSA

ONSET OR EXACERBATION OF ARTHROPATHY

STROKE

MYOCARDIAL INFARCTION

FIBROMYALGIA

ALL-CAUSE MORTALITY

OCULORESPIRATORY SYNDROME

CONCLUDING SECTION

REFERENCES

INTRODUCTION

ACUTE DISSEMINATED ENCEPHALOMYELITIS

TRANSVERSE MYELITIS

MULTIPLE SCLEROSIS

GUILLAIN-BARRÉ SYNDROME

CHRONIC INFLAMMATORY DISSEMINATED POLYNEUROPATHY

BELL'S PALSY

ANAPHYLAXIS

AUTOIMMUNE HEPATITIS

CONCLUDING SECTION

REFERENCES

INTRODUCTION

ENCEPHALITIS AND ENCEPHALOPATHY

SEIZURES

ACUTE DISSEMINATED ENCEPHALOMYELITIS

TRANSVERSE MYELITIS

OPTIC NEURITIS

NEUROMYELITIS OPTICA

MULTIPLE SCLEROSIS ONSET IN ADULTS

MULTIPLE SCLEROSIS ONSET IN CHILDREN

MULTIPLE SCLEROSIS RELAPSE IN ADULTS

MULTIPLE SCLEROSIS RELAPSE IN CHILDREN

FIRST DEMYELINATING EVENT IN ADULTS

FIRST DEMYELINATING EVENT IN CHILDREN

GUILLAIN-BARRÉ SYNDROME

CHRONIC INFLAMMATORY DISSEMINATED POLYNEUROPATHY

BRACHIAL NEURITIS

ANAPHYLAXIS

ERYTHEMA NODOSUM

ONSET OR EXACERBATION OF SYSTEMIC LUPUS ERYTHEMATOSUS

ONSET OR EXACERBATION OF VASCULITIS

ONSET OR EXACERBATION OF POLYARTERITIS NODOSA

ONSET OR EXACERBATION OF PSORIATIC ARTHRITIS

ONSET OR EXACERBATION OF REACTIVE ARTHRITIS

ONSET OR EXACERBATION OF RHEUMATOID ARTHRITIS

ONSET OR EXACERBATION OF JUVENILE IDIOPATHIC ARTHRITIS

TYPE 1 DIABETES

FIBROMYALGIA

CONCLUDING SECTION

REFERENCES

INTRODUCTION

ACUTE DISSEMINATED ENCEPHALOMYELITIS

TRANSVERSE MYELITIS

NEUROMYELITIS OPTICA

MULTIPLE SCLEROSIS

GUILLAIN-BARRÉ SYNDROME

CHRONIC INFLAMMATORY DISSEMINATED POLYNEUROPATHY

BRACHIAL NEURITIS

AMYOTROPHIC LATERAL SCLEROSIS

ANAPHYLAXIS

TRANSIENT ARTHRALGIA

PANCREATITIS

THROMBOEMBOLIC EVENTS

HYPERCOAGULABLE STATES

CONCLUDING SECTION

REFERENCES

INTRODUCTION

ENCEPHALITIS AND ENCEPHALOPATHY

INFANTILE SPASMS

SEIZURES

ATAXIA

AUTISM

ACUTE DISSEMINATED ENCEPHALOMYELITIS

TRANSVERSE MYELITIS

OPTIC NEURITIS

MULTIPLE SCLEROSIS ONSET IN ADULTS

MULTIPLE SCLEROSIS RELAPSE IN ADULTS

MULTIPLE SCLEROSIS RELAPSE IN CHILDREN

GUILLAIN-BARRÉ SYNDROME

CHRONIC INFLAMMATORY DISSEMINATED POLYNEUROPATHY

OPSOCLONUS MYOCLONUS SYNDROME

BELL'S PALSY

ANAPHYLAXIS

CHRONIC URTICARIA

SERUM SICKNESS

ARTHROPATHY

TYPE 1 DIABETES

MYOCARDITIS

FIBROMYALGIA

SUDDEN INFANT DEATH SYNDROME

IMMUNE THROMBOCYTOPENIC PURPURA

CONCLUDING SECTION

REFERENCES

INTRODUCTION

ENCEPHALITIS AND ENCEPHALOPATHY

ACUTE DISSEMINATED ENCEPHALOMYELITIS

TRANSVERSE MYELITIS

MULTIPLE SCLEROSIS

GUILLAIN-BARRÉ SYNDROME

CHRONIC INFLAMMATORY DISSEMINATED POLYNEUROPATHY

ANAPHYLAXIS

CHRONIC HEADACHE

CONCLUDING SECTION

REFERENCES

COMPLEX REGIONAL PAIN SYNDROME

DELTOID BURSITIS

SYNCOPE

CONCLUDING SECTION

REFERENCES

MMR vaccine

Varicella vaccine

Anaphylaxis

REFERENCES

Appendix A Glossary

Appendix B List of Adverse Events

Appendix C Literature Search Strategy

Appendix D Causality Conclusion Tables

Appendix E References

Appendix F Committee Biosketches

Appendix G Meeting Agendas

Expand All

Collapse All

This study was supported by Contract No. HHSH230200446009I, Task Order 13 between the National Academy of Sciences and the Health Resources and Services Administration of the U.S. Department of Health and Human Services. The Centers for Disease Control and Prevention and the National Vaccine Program Office also provided support through that contract. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the view of the organizations or agencies that provided support for this project.

Suggested citation:

IOM (Institute of Medicine). 2012. Adverse effects of vaccines: Evidence and causality. Washington, DC: The National Academies Press.

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. The members of the committee responsible for the report were chosen for their special competences and with regard for appropriate balance.

[greatestlcve]

Paracetamol ACTAVIS Uses, Dosage, Side Effects, Precautions &Warnings

Drug Online

paracetamol actavis 500 mg tablets Generic drug of the therapeutic class: Analgesics active ingredients: Paracetamol

paracetamol ACTAVIS tablets 500mg information

This medicine contains paracetamol.

It is indicated in case of pain and / or fever such as headaches, flu, dental pain, body aches, painful periods.

This presentation is for adults and children from 27 kg (from about 8 years) .

For children with different weights, there are other paracetamol presentations: ask your doctor or pharmacist for advice.

paracetamol actavis used for and indication?

Symptomatic treatment of mild to moderate pain and / or febrile conditions.

Paracetamol ACTAVIS Dosage

Dosage

The dosage of paracetamol depends on the weight of the child; ages are mentioned for information.

If you do not know the child’s weight, weigh it to give the best dose.

Paracetamol exists in many dosages, allowing to adapt the treatment to the weight of each child.

The recommended daily dose of paracetamol is approximately 60 mg / kg / day, divided into 4 or 6 doses, approximately 15 mg / kg every 6 hours or 10 mg / kg every 4 hours.

This presentation is reserved for adults and children from 27 kg (from about 8 years old).

For children weighing between 27 and 40 kg (approximately 8 to 13 years), the dosage is 1 capsule 500 mg per dose, to be renewed if necessary after 6 hours, without exceeding 4 capsules per day.

For children weighing between 41 and 50 kg (approximately 12 to 15 years), the dosage is 1 capsule 500 mg per dose, to be renewed if necessary after 4 hours, without exceeding 6 capsules per day.

For adults and children weighing more than 50 kg (starting at about 15 years of age), the usual dosage is 1 to 2 capsules at 500 mg per dose, depending on the intensity of the pain, to be repeated in case of need after 4 hours minimum.

It is generally not necessary to exceed 3 g of paracetamol per day, or 6 capsules per day.

However, in case of more intense pain and on the advice of your doctor, the total dose can be increased up to 4 g per day, or 8 capsules per day.

However:

doses higher than 3 g paracetamol per day require medical advice.

NEVER TAKE MORE THAN 4 GRAMS OF PARACETAMOL PER DAY (taking into account all medicines containing paracetamol in their formula).

Always observe at least 4 hours between shots.

In case of severe kidney disease (severe renal failure), the doses should be 8 hours apart and the total dose should not exceed 3 tablets per day (3 g).

If you have the impression that the effect of PARACETAMOL SANDOZ 500 mg capsule is too strong or too weak, talk to your doctor or pharmacist.

Administration mode

Oral way.

The capsules are swallowed as is with a drink (eg water, milk, fruit juice).

Capsule taking is contraindicated in children under 6 years of age because it can swallow sideways and choke. Use another form.

In addition, if your child has a fever over 38.5 ° C, you can improve the effectiveness of the drug treatment by:

discover your child,

drink it,

do not leave your child in a place that is too hot.

Frequency of administration

Systematic catches prevent pain or fever oscillations.

In children, they should be regularly spaced, including at night, preferably 6 hours, and at least 4 hours.

In adults, they must be spaced at least 4 hours apart.

In case of severe kidney disease (severe renal failure), the catch will be spaced 8 hours apart.

Contraindications

Paracetamol hypersensitivity

Hepatocellular insufficiency

Child before 6 years old

– Hypersensitivity to paracetamol and / or to other constituents.

– Hepatocellular insufficiency.

Taking a tablet or capsule is contraindicated in children before 6 years of age because it can lead to a false route.

How it works Paracetamol ACTAVIS

ABSORPTION :

The oral absorption of paracetamol is complete and rapid. Maximum plasma concentrations are reached 30 to 60 minutes after ingestion.

DISTRIBUTION :

Paracetamol is distributed rapidly in all tissues. The concentrations are comparable in blood, saliva and plasma. Plasma protein binding is low.

METABOLISM :

– Paracetamol is metabolized mainly in the liver. The two major metabolic pathways are glucuronidation and sulfoconjugation. The latter pathway is rapidly saturable at dosages higher than the therapeutic doses.

– A minor pathway, catalyzed by cytochrome P450, is the formation of a reactive intermediate, (N-acetyl benzoquinoneimine), which, under normal conditions of use, is rapidly detoxified by reduced glutathione and eliminated in the urine after conjugation to cysteine ​​and mercaptopuric acid.

On the other hand, during massive intoxications, the quantity of this toxic metabolite is increased.

ELIMINATION :

– The elimination is essentially urinary. 90% of the ingested dose is eliminated by the kidney in 24 hours, mainly in the form of glucuroconjugate (60 to 80%) and sulfoconjugate (20 to 30%). Less than 5% is eliminated unchanged.

– The elimination half-life is approximately 2 hours.

PHYSIOLOGICAL VARIATIONS :

Renal impairment : In patients with severe renal impairment (creatinine clearance <10 ml / min), paracetamol and its metabolites are delayed.

– Elderly : Conjugacy capacity is not changed.

paracetamol actavis side effects

The undesirable effects are listed below by class of organ systems and by frequency group. Frequency groups are defined as follows: very common (≥1 / 10); frequent (≥1 / 100, <1/10); uncommon (≥1 / 1,000, <1/100); rare(≥1 / 10,000, <1/1000); very rare (<1 / 10,000), or indeterminate frequency (can not be estimated based on available data).

Blood and lymphatic system disorders

· Very rare : thrombocytopenia, agranulocytosis, leukopenia, neutropenia, pancytopenia.

Immune system disorders

· Rare : hypersensitivity, Quincke’s deme.

· Not known : anaphylactic shock, Stevens Johnson syndrome, Lyell syndrome.

The occurrence of these reactions requires the definitive discontinuation of this drug and related drugs.

Hepatobiliary disorders

· Rare : Elevated liver enzymes.

Skin and subcutaneous tissue disorders

· Rare : rash, pruritus, erythema, urticaria.

· Very rare : cases of severe skin reactions.

The occurrence of these reactions requires the definitive discontinuation of this drug and related drugs

Paracetamol ACTAVIS Interactions

Associations subject to precautions for use

 Oral anticoagulants

The anticoagulant effect of warfarin and other coumarins may be increased by regular and prolonged use of paracetamol, resulting in increased bleeding risk. Occasional use of paracetamol has no significant effect.

Regular control of the INR. Possible adaptation of oral anticoagulant dosage during paracetamol treatment and after discontinuation.

Associations to consider

Hepatotoxic substances (eg phenytoin, phenobarbital, carbamazepine, rifampicin, isoniazid)

Concomitant administration of hepatotoxic substances may increase the risk of accumulation and therefore overdose with paracetamol. The risk of hepatotoxicity of paracetamol may be increased by drugs that induce microsomal liver enzymes, such as barbiturates, anti-epileptics (eg phenytoin, phenobarbital, carbamazepine) and antituberculous drugs (rifampicin, isoniazid).

Alcohol

The hepatotoxicity of paracetamol may be aggravated by chronic or excessive ingestion of alcohol (see Warnings and Precautions for Use section ).

Chloramphenicol

The elimination half-life of chloramphenicol can be prolonged by concomitant administration of paracetamol.

Cholestyramine

Paracetamol absorption may be reduced with simultaneous administration of cholestyramine, but this reduction is small if cholestyramine is administered one hour later.

Domperidone

Domperidone can accelerate the absorption of paracetamol.

Metoclopramide

Metoclopramide accelerates the absorption of paracetamol and increases its peak plasma concentrations.

Probenecide

Probenecid disrupts the metabolism of paracetamol. In patients on probenecid therapy, the dose of paracetamol should be decreased.

 Zidovudine

Regular use of paracetamol along with zidovudine may result in neutropenia and increase the risk of liver injury.

Interactions with paraclinical examinations

Taking paracetamol may interfere with the glucose-glucose oxidase-peroxidase assay at abnormally high concentrations.

Taking paracetamol may interfere with the determination of blood uric acid by the phosphotungstic acid method.

Paracetamol ACTAVIS Warnings and Precautions

WARNINGS

This presentation is RESERVED FOR ADULTS and the CHILD from 27 kg (ie from about 8 years).

– To avoid a risk of overdose, check the absence of paracetamol in the composition of other drugs.

– Maximum recommended doses :

. in children under 37 kg , the total dose of paracetamol should not exceed 80 mg / kg / day (see section on overdose).

. in children from 38 kg to 50 kg , the total dose of paracetamol should not exceed 3 g per day (see section on overdose).

. in adults and children over 50 kg , paracetamol THE TOTAL RATE SHALL NOT EXCEED 4 GRAMS PER DAY (see Overdose).

– Capsule taking is contraindicated in children under 6 years of age because it can lead to a false route.

PRECAUTIONS

In children treated with 60 mg / kg / day of paracetamol, the combination of another antipyretic is justified only in case of inefficiency.

Drive and use machines

This medicine has no or negligible effect on the ability to drive and use machines.

PREGNANCY / BREAST FEEDING / FERTILITY

paracetamol actavis DURING pregnancy

Studies in animals have not shown any teratogenic or foetotoxic effect of paracetamol.

Clinically, the results of epidemiological studies seem to exclude a particular malformative or fetotoxic effect of paracetamol.

As a result, paracetamol, under normal conditions of use, may be prescribed throughout pregnancy.

Breast-feeding 

At therapeutic doses, administration of this drug is possible during breastfeeding.

In case of overdose or accidental poisoning, PREVENT MEDICAL ATTENTION IN EMERGENCY.

What is  Forms and Composition?

COMPOSITION   

Paracetamol. 500 mg

For a capsule.

Excipient with known effect: red cochineal A (E124).

For the full list of excipients, see section 6.1.

  PHARMACEUTICAL FORM    

Capsule.

NOT’s

Edrug-online contains comprehensive and detailed information about drugs available in the medical field, and is divided into four sections:

general information:

Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

Additional information:

General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

Special warnings:

For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

Side effects:

It treats possible side effects and drug interactions that require attention and its effect on continuous use.

The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

The post Paracetamol ACTAVIS Uses, Dosage, Side Effects, Precautions &Warnings appeared first on Drug Online.

from Drug Online https://bit.ly/2AqHbm2 via Edrug Online from Faculty of Medicine https://bit.ly/3iZgtS1 via Internal Medicine

[trinitydigest]

Immune Thrombocytopenia Market Insights, Epidemiology, and Pipeline Insights – 2017-30

http://dlvr.it/RXRJQ2

[columbianewsupdates]

Immune thrombocytopenia Epidemiology Insights, Analysis, and Forecasted Trends – 2017-30

http://dlvr.it/RXR7ZM

[technewspoint]

Immune Thrombocytopenia Market Insights, Epidemiology, and Pipeline Insights – 2017-30

http://dlvr.it/RXQwMT

[cheyennejournal]

Immune thrombocytopenia Epidemiology Insights, Analysis, and Forecasted Trends – 2017-30

http://dlvr.it/RXQrJs

[newsheadlinesnow]

Immune thrombocytopenia Epidemiology Insights, Analysis, and Forecasted Trends – 2017-30

http://dlvr.it/RXQpwb

[kritikarehani]

Hemophagocytic Lymphohistiocytosis (HLH) Market

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disorder characterized by unbridled activation of cytotoxic T lymphocytes, natural killer (NK) cells, and macrophages resulting in hypercytokinemia and immune-mediated injury of multiple organ systems.

DelveInsight’s ‘Hemophagocytic Lymphohistiocytosis Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Hemophagocytic Lymphohistiocytosis (HLH) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 

The Hemophagocytic Lymphohistiocytosis market report provides analysis regarding current treatment practices, an emerging drug-like Tadekinig Alfa, potential therapies, market share of the individual therapies, and historical, current and forecasted Hemophagocytic Lymphohistiocytosis market size from 2017 to 2030 segmented by seven major markets.

The report also covers current Hemophagocytic Lymphohistiocytosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Request for sample pages: https://www.delveinsight.com/sample-request/hemophagocytic-lymphohistiocytosis-market

Geography Covered

The United States

 EU5 (Germany, France, Italy, Spain, and the     United Kingdom)

 Japan

Study Period: 2017–2030

Hemophagocytic Lymphohistiocytosis – Disease Understanding and Treatment Algorithm

Hemophagocytic Lymphohistiocytosis Overview

HLH is a condition with different underlying causes. There are several names used to describe this condition. While familial hemophagocytic lymphohistiocytosis (FHL) refers to genetic forms that are caused by an abnormal variant in a gene, macrophage activation syndrome (MAS) is the term used for hemophagocytic lymphohistiocytosis that occurs in people with an autoimmune or autoinflammatory disease; this is a type of secondary HLH.

The onset and severity of hemophagocytic lymphohistiocytosis can vary greatly from one person to another. Generally, affected individuals develop fevers, a rash, an abnormally large liver (hepatomegaly), and an abnormally large spleen (splenomegaly). However, these initial sign and symptoms are described as nonspecific. Affected individuals may also have anemia, thrombocytopenia, neurological symptoms including seizures, changes in mental status and irritability, paralysis (palsy) of certain cranial nerves, and problems coordinating voluntary movements (ataxia).

View report: https://www.delveinsight.com/report-store/hemophagocytic-lymphohistiocytosis-market

Hemophagocytic Lymphohistiocytosis Treatment

This chapter covers the details of conventional and current medical therapies available in the Hemophagocytic Lymphohistiocytosis market for the treatment of the condition. It also provides the country-wise Hemophagocytic Lymphohistiocytosis treatment guidelines across the United States, Europe and Japan.

DelveInsight’s Hemophagocytic Lymphohistiocytosis market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Hemophagocytic Lymphohistiocytosis treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Hemophagocytic Lymphohistiocytosis Epidemiology

The Hemophagocytic Lymphohistiocytosis epidemiology chapters provide insights about historical and current Hemophagocytic Lymphohistiocytosis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Hemophagocytic Lymphohistiocytosis epidemiology is segmented by Incidence of Hemophagocytic Lymphohistiocytosis (Familial and secondary HLH), Familial HLH cases by Mutation Types and Secondary HLH cases by Etiologies. The report includes a thorough analysis of all segmentations.

Incidence of Hemophagocytic Lymphohistiocytosis can be divided into two subtypes: familial or primary HLH cases and secondary HLH cases. In the US, the cases of familial Hemophagocytic Lymphohistiocytosis were found to be 100 in 2017. Moreover, the cases of secondary HLH were reported to be 315 in the country.

According to DelveInsight’s, the total incident population of Hemophagocytic Lymphohistiocytosis in seven major markets was 4,435 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).

Among all the seven major markets, Germany accounts for the highest number of Hemophagocytic Lymphohistiocytosis cases.

Hemophagocytic Lymphohistiocytosis Drug Chapters

Drug chapter segment of the Hemophagocytic Lymphohistiocytosis report encloses the detailed analysis of Hemophagocytic Lymphohistiocytosis pipeline drug. It also helps understand the Hemophagocytic Lymphohistiocytosis clinical trial details, expressive pharmacological action, agreements of included drug and the latest news and press releases.

The best treatment options for hemophagocytic lymphohistiocytosis (HLH) are determined by several factors, including the severity of symptoms, the age of onset, and the underlying cause of the condition. Treatment in adults has been based on the HLH-94 study, a large prospective pediatric study conducted by The Histiocyte Society in patients <16 years old with no history of immunosuppression or malignancy. AB2 Bio’s Tadekinig Alfa is the only therapy in the pipeline.

Hemophagocytic Lymphohistiocytosis Market Outlook

The Hemophagocytic Lymphohistiocytosis market size is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, France accounts for the largest Hemophagocytic Lymphohistiocytosis market size with USD 1.3 million in 2017, while Japan had the smallest market size of HLH with USD 0.2 million in 2017.

Some Frequently Asked Questions:

Which geography accounted for the largest Hemophagocytic Lymphohistiocytosis market size?

France accounted for the largest Hemophagocytic Lymphohistiocytosis market size.

What is forecasted Hemophagocytic Lymphohistiocytosis market size in 2030?

DelveInsight estimates an increase in HLH Market Size during the study period, 2017–2030

What are the present Hemophagocytic Lymphohistiocytosis market drivers?

Increasing prevalence of risk factors and research opportunities.

What are the Hemophagocytic Lymphohistiocytosis market barriers?

Toxicity of therapies, lack of specialized therapies, and lack of alternative treatments.

How many companies are developing drugs for Hemophagocytic Lymphohistiocytosis?

Currently, only one key pharma player is developing a drug for Hemophagocytic Lymphohistiocytosis.

Which are the leading companies in Hemophagocytic Lymphohistiocytosis market?

Key Player – AB2 Bio

How is epidemiology segmented for Hemophagocytic Lymphohistiocytosis?

Incidence of Hemophagocytic Lymphohistiocytosis, Familial HLH cases by Mutation Types and Secondary HLH cases by Etiologies.

Download sample pages: https://www.delveinsight.com/sample-request/hemophagocytic-lymphohistiocytosis-market